Association of MICA-129Met/Val polymorphism with clinical outcome of anti-TNF therapy and MICA serum levels in patients with rheumatoid arthritis

被引:0
|
作者
Milena Iwaszko
Jerzy Świerkot
Marta Dratwa
Barbara Wysoczańska
Lucyna Korman
Bartosz Bugaj
Katarzyna Kolossa
Sławomir Jeka
Piotr Wiland
Katarzyna Bogunia-Kubik
机构
[1] Polish Academy of Sciences,Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy
[2] Wrocław Medical University,Department of Rheumatology and Internal Medicine
[3] UMK,Jan Biziel University Hospital No. 2, Department of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Collegium Medicum in Bydgoszcz
来源
The Pharmacogenomics Journal | 2020年 / 20卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
MHC class I polypeptide-related sequence A (MICA) is a stress-induced protein involved in activation of NK and T cells through interaction with NKG2D receptor. These molecules are atypically expressed in synovium of patients diagnosed with rheumatoid arthritis (RA). A total of 279 patients with RA, qualified to TNF-blockade therapy, were genotyped for MICA rs1051792 SNP. The effectiveness of anti-TNF agents was assessed with European League Against Rheumatism criteria. Significant relationship between MICA rs1051792 and outcome of TNF-blockade therapy has been found. The MICA rs1051792 GG genotype was overrepresented in patients non-responsive to anti-TNF drugs in comparison with other genotypes (p = 0.010). On the other hand, beneficial therapeutic response was more frequently detected among RA subjects possessing heterozygous genotype than those with homozygous genotypes (p = 0.003). Furthermore, increased MICA concentrations in serum were observed in patients possessing MICA rs1051792 GG genotype as compared with those with GA or AA genotypes (p = 1.8 × 10−5). The results from this study indicate the potential influence of MICA rs1051792 polymorphism on modulation of therapeutic response to TNF-blockade treatment in RA.
引用
收藏
页码:760 / 769
页数:9
相关论文
共 50 条
  • [21] Association of MICA gene polymorphism and MICA-129 Val/Met dimorphism (weak/strong binders of the NKG2D receptor) with susceptibility to inflammatory bowel disease
    Lopez, Ruth
    Salgado, Gema
    Valdes, Mariano
    Campillo, Jose A.
    Lucas, Daniel
    Salama, Hortensia
    Martinez, Pedro
    Boix, Francisco
    Botella, Carmen
    Minguela, Alfredo
    Miras, Manuel
    Alvarez-Lopez, Maria R.
    Carballo, Fernando
    Muro, Manuel
    TISSUE ANTIGENS, 2010, 75 (05): : 612 - 613
  • [22] CLINICAL SIGNIFICANCE OF SERUM MATRIX METALLOPROTEINASE-3 NORMALISATION IN RHEUMATOID ARTHRITIS PATIENTS WITH ANTI-TNF THERAPY
    Hattori, Y.
    Kaneko, A.
    Kida, D.
    Takahashi, N.
    Ishikawa, H.
    Kanda, H.
    Sato, T.
    Kojima, T.
    Ishiguro, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 487 - 488
  • [23] SERUM LEVELS OF THE ANTI-TNF BIOLOGICS CORRELATE WITH CLINICAL EFFICACY IN PATIENTS WITH INFLAMMATORY ARTHRITIS
    Mok, C. C.
    Fong, B.
    Ho, L. Y.
    To, C. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 825 - 825
  • [24] Serum Levels of the Anti-TNF Biologics Correlate with Clinical Efficacy in Patients with Inflammatory Arthritis
    Mok, Chi Chiu
    Fong, Lai Shan
    Ho, Ling Yin
    To, Chi Hung
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [25] Serum protein profile of rheumatoid arthritis treated with anti-TNF therapy (infliximab)
    Takeuchi, Tohru
    Nakanishi, Toyofumi
    Tabushi, Yoko
    Hata, Ayu
    Shoda, Takeshi
    Kotani, Takuya
    Shimizu, Akira
    Takubo, Takayuki
    Makino, Shigeki
    Hanafusa, Toshiaki
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 855 (01): : 66 - 70
  • [26] PATIENTS' EXPERIENCE OF ANTI-TNFα THERAPY IN RHEUMATOID ARTHRITIS: A QUALITATIVE STUDY
    Marshall, N. J.
    Wilson, G.
    Lapworth, K.
    Kay, L. J.
    RHEUMATOLOGY, 2004, 43 : 42 - 42
  • [27] CHANGES OF METABOLIC BIOMARKER LEVELS UPON ANTI-TNF THERAPY IN RHEUMATOID ARTHRITIS
    Pusztai, A.
    Vegh, E.
    Horvath, A.
    Szanto, S.
    Szucs, G.
    Hamar, A.
    Domjan, A.
    Hodosi, K.
    Seres, I.
    Kerekes, G.
    Szekanecz, Z.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : A44 - A45
  • [28] Predicting response to anti-TNFα therapy among patients with rheumatoid arthritis
    Hyrich, K
    Watson, K
    Symmons, D
    Silman, A
    RHEUMATOLOGY, 2005, 44 : I24 - I24
  • [29] Insulin resistance in patients with rheumatoid arthritis:: effect of anti-TNFα therapy
    Rosenvinge, A.
    Krogh-Madsen, R.
    Baslund, B.
    Pedersen, B. K.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2007, 36 (02) : 91 - 96
  • [30] Patients and carers experience of the benefits of Anti-TNF therapy for rheumatoid arthritis
    Kinder, AJ
    Samanta, A
    Edwards, J
    Clarke, A
    RHEUMATOLOGY, 2005, 44 : I70 - I70